Skip to main content

Advertisement

Table 3 Medicationa reported by the GPs in intervention group and control group at T1 and T2 and the medication recommendations of the AMSS

From: The feasibility of an allergy management support system (AMSS) for IgE-mediated allergy in primary care

  Intervention group (n = 35) Control group (n = 18)
T1 AMSS T2 T1 AMSSb T2
Antihistamines
 Nasal 2 (6) 1 (3) 3 (9) 0 1 (6) 0
 Ocular 2 (6) 0 2 (6) 1 (6) 0 1 (6)
 Oral 10 (29) 20c (57) 15 (43) 4 (22) 7 (39) 4 (22)
Corticosteroids
 Nasal 9 (26) 16 (46) 15 (43) 3 (17) 9 (50) 4 (22)
 Pulmonary 4 (11) 5 (14) 6 (17) 2 (11) 2 (11) 1 (6)
 Oral 0 0 0 1 (6) 0 1 (6)
 Cutaneous class 1 1 (3) 2 (6) 1 (3) 0 2 (11) 0
 Cutaneous class 2 1 (3) 3 (9) 1 (3) 0 3 (17) 0
 Cutaneous class 3 0 0 0 1 (6) 1 (6) 1 (6)
 Cutaneous class 4 0 0 0 0 0 0
B-sympathicomimetics
 Short-acting 7 (20) 20 (57) 9 (26) 3 (17) 13 (72) 4 (22)
 Long-acting 0 0 1 (3) 0 1 (6) 0
Leukotrien antagonists 0 0 0 1 (6) 0 1 (6)
Combination therapy (corticosteroids with B-sympathicomimetics) 0 1 (3) 1 (3) 2 (11) 0 2 (11)
Decongestants 0 0 0 0 0 0
Emollients 1 (3) 7 (20) 1 (3) 1 (6) 5 (28) 1 (6)
Epinephrine auto-injector 0 8 (23) 2 (6) 0 3 (17) 0
  1. GPs did not report considering immunotherapy for any patients. The AMSS advised immunotherapy as a follow-up option after instituting pharmacotherapy 16 times (46%) in the intervention group and 9 times (50%) in the control group. The AMSS advised venom immunotherapy for a single patient
  2. aPresented as n (%)
  3. bGPs in the control group did not receive AMSS recommendations. The AMSS formulated these recommendations for evaluative purposes only
  4. cFor two persons the AMSS advised H2 antagonist as urticaria medication